DiObex Licenses Worldwide Rights to Cortisol Inhibitors

DiObex, a biotechnology company developing therapeutics for the treatment of metabolic diseases, announced the conclusion of a worldwide exclusive license agreement with Cortendo Invest AB of Gothenburg, Sweden. The license covers patents, patent applications, intellectual property, data and certain other assets relating to novel inhibitors of Cortisol synthesis. Included within the licensed assets is an issued patent which broadly covers the field of Cortisol synthesis inhibition for treatment of metabolic diseases such as Type 2 Diabetes and Metabolic Syndrome.

BioSpace (http://www.biospace.com/news_story.cfm?StoryID=19647120&full=1)